Bullish & Foolish
Full MAIA fundamentals All 466 on the Survival Watch

MAIAMAIA BIOTECHNOLOGY, INC.

Is Maia Biotechnology struggling financially?

Yes, by its own account. Maia Biotechnology told the SEC on 23 Mar 2026, in Form 10-K, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed Mar 2026

7/100

Critical

Sector
Biotech/Pharma
Market cap
$84.5M
Source filing
10-K 23 Mar 2026
Balance sheet
30 Jun 2026

Cash runway

  • 0months

    If the burn speeds up

    Empty by Jun 2026

  • 1month

    If it eases off

    Empty by Jul 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$0

÷

Cash burned over the last 12 months

$36.2M

What Maia Biotechnology told the SEC

…its obligations for at least twelve months from the issuance date of this report. As a result of receiving these proceeds, management has concluded that substantial doubt regarding the Company’s ability to continue as a going concern no longer exists. F-…

MAIA BIOTECHNOLOGY, INC., Form 10-K, filed 23 Mar 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 83.0% share-count increase The company issued stock. Each share now owns 45.4% less of the business than a year ago, before any change in the price.
  • Cash burn is increasing It is spending 28% more cash per year than it was, so the runway above shortens even if nothing else changes.

Other Biotech/Pharma companies that filed the doubt